摘要
目的 探讨β2微球蛋白（β2-MG）和血管内皮生长因子（VEGF）在弥漫大B细胞淋巴瘤（DLBCL）中的表达及意义.方法 Luminex液相芯片法检测初治49例DLBCL患者治疗前血清VEGF 和β2-MG蛋白表达水平的变化,分析二者与临床病理因素的关系.结果 49例DLBCL患者中,β2-MG 高表达37例,VEGF高表达23例.β2-MG和VEGF蛋白高表达与患者的性别、年龄、有无B组症状、临床分期、乳酸脱氢酶（LDH）的增高均无相关性（均P＞ 0.05）.β2-MG高表达与以CHOP方案为基础的全身化疗效果相关（P=0.037）.VEGF蛋白高表达与合并纵隔侵犯有相关趋势,但差异无统计学意义（P=0.067）.结论 蛋白芯片法检测β2-MG和VEGF蛋白表达水平有望成为DLBCL常规临床诊断和治疗方案选择的新方法.
Objective To investigate the expression and clinical significance of β2 microglobin （β2-MG）protien and vascular endothelial growth factor （VEGF） protien in diffuse large B-cell lymphoma （DLBCL）.Methods The expressions of VEGF protien and β2-MG protien were evaluated in 49 DLBCL patients which started the initial treatment by luminex suspension array.Results Among 49 DLBCL patients,expression of β2-MG protein was high in 37 cases and the expression of VEGF protein was high in 23 cases.The expression of VEGF protien and β2-MG protien were not related with gender,age,B symptoms,clinical stage and lactic acid （LDH）.There was positive correlation between the high expression of β2-MG protien and chemotherapy （P =0.037）.There was relevant trend between the higher expression of VEGF protien （P =0.067）.Conclusion The expressions of VEGF protien and β2-MG protien are detected in DLBCL,both proteins may be the potencial markers of DLBCL and therapeutic targets for DLBCL.
出处
《肿瘤研究与临床》
CAS
2013年第10期678-680,共3页
Cancer Research and Clinic
基金
江苏省肿瘤医院科研基金（ZM201203）
